Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The prevalence of gastric cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline,
Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC, Dec. 21, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with...
/PRNewswire/ -- DelveInsight's 'Gastric Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented new clinical data for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective ...